Listen to our exclusive interview with Philip A Philip to find out about novel agents and strategies on the horizon for pancreatic cancer.
In this interview, Illumina’s Chief Scientist, David Bentley, speaks about the 100,000 Genomes Project which could transform the way cancer patients are cared for.
Listen to this exclusive interview with Dirk Arnold from Klinik für Tumorbiologie (Freiburg, Germany) about current treatment options for rectal cancer, how we can define a strategy for oligometastic rectal cancer and his hopes for the future of this field.
Editor, Jade Parker recently spoke with world-renowned sarcoma expert, Robin L Jones. In this interview discover challenges in the diagnosis, treatment and clinical trials of sarcoma and other rare tumors.
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this group of patients.
Listen to this exclusive interview with Peter Stern (University of Manchester, UK) to discover more about chemotherapy resistance in acute lymphoblastic leukemia and novel strategies to overcome it.
Editor, Jade Parker recently spoke with David Adams, Wellcome Trust Sanger Institute (Cambridge, UK) about utilizing DNA sequencing of patients and genetic screens in human cells and mice to identify cancer genes and genetic interactions.
In this interview with Francesco Lo-coco we discussed a randomized clinical trial conducted with the drug Trisenox as well as, the genetic characterization, monitoring and treatment of hematologic tumors, particularly acute promyelocytic leukemia.
Editor Jade Parker, speaks to Peter Campbell (Wellcome Trust Sanger Institute, Cambridge, UK) to find out how he is working towards identifying the preventable causes of cancer.
In this interview find out about Anthony Nolan’s research strategy, breakthroughs that have aided the advancement of stem cell transplantation, how third-generation sequencing for HLA typing may improve donor-recipient matching and the direction that Alejandro Madrigal envisions Anthony Nolan’s research will take in the coming years.